ClinicalTrials.gg
CompletedNCT00844844aHUSUpdated Jul 23, 2015Results posted

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS

A Phase 2 interventional study of Eculizumab in Atypical Hemolytic Uremic Syndrome, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 17 sites in 5 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-07-23.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing eculizumab in Atypical Hemolytic Uremic Syndrome — 1 open to participants now, 1 under way, 1 of them phase 3. eculizumab · Atypical Hemolytic Uremic Syndrome.

Enrollment
10th of 10
1 · median 19
Started
2009
with 3 others
Phase 2
8 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
7 of 10
Alexion Pharmaceuticals, Inc.

Among the 10 studies testing eculizumab in Atypical Hemolytic Uremic Syndrome, this one is the 10th largest by enrollment, is one of 4 that started in 2009, is one of 8 in phase 2, and was the 3rd registered.

Atypical Hemolytic Uremic Syndrome

45 studies on the registry are indexed under Atypical Hemolytic Uremic Syndrome; 14 are open to participants now.

Browse Atypical Hemolytic Uremic Syndrome studies →

Open to participants now

1 of the 10 studies testing eculizumab in Atypical Hemolytic Uremic Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Atypical Hemolytic Uremic Syndrome studies recruiting now, 10 (83%) set no upper age limit and none (0%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing eculizumab in Atypical Hemolytic Uremic Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).

03

Conditions studied

  • Atypical Hemolytic Uremic Syndrome

Keywords

  • aHUS
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients from 12 and up to 18 years weighing ≥ 40 kg who have been diagnosed with Atypical Hemolytic-Uremic Syndrome (aHUS).
  2. Decrease in count despite at least 4 plasma therapy (PT) treatments in the 1 week immediately prior to screening.

    1. Screening platelet count , \< 150 x10\^9/L and at least 25% lower than the average remission platelet count or
    2. If remission counts not available, platelet count at onset of the current aHUS episode must be ≤75x10\^9/L and platelet count at screening must be ≤ 100 x 10\^9/L despite PT treatment administration of at least 4 PT treatments in the 1 week immediately prior to screening
  3. Known complement regulatory protein genetic abnormality
  4. Lactate dehydrogenase (LDH) level ≥ unless the patient has been receiving plasma exchange and LDH at the onset of the current aHUS episode was at least the ULN. If LDH is normal at screening, other markers indicative of ongoing hemolysis such as haptoglobin, schistocytes should be evaluated and discussed with Sponsor
  5. Creatinine level ≥ ULN for age
  6. Female patients of must be practicing an effective, reliable and medically approved regimen during the entire duration of the study, including the follow-up period and for up to 5 months following of eculizumab treatment discontinuation.
  7. Patient's parents/legal guardian must be willing and able to give written and patient must be willing to give written informed assent.
  8. Able and willing to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. TTP, (defined as ADAMTS-13 activity \<5%) from an historical observation (prior to initiation of plasma therapy) or as tested at the screening visit by the central laboratory
  2. within 5 years of screening.
  3. Typical HUS (Shiga toxin +).
  4. Known infection.
  5. Identified drug exposure-related HUS.
  6. Infection-related HUS.
  7. HUS related to bone marrow transplant
  8. HUS related to vitamin B12 deficiency
  9. Renal function status requiring chronic dialysis
  10. Patients with a confirmed diagnosis of sepsis
  11. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease.
  12. Pregnancy or lactation.
  13. Unresolved meningococcal disease.
  14. Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody positivity or syndrome.
  15. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.
  16. Patients who have received previous treatment with eculizumab
  17. Patients receiving IVIG within 8 weeks or Rituximab therapy within 12 weeks of screening.
  18. Patients receiving other therapies such as , mTOR inhibitors or tacrolimus are excluded unless: [1] part of an established post-transplant anti-rejection regime, [2] patient has confirmed anti-CFH antibody requiring immunosuppressive therapy, and [3] dose of such medications have been unchanged for at least 4 weeks prior to the screening period or [4] patient is experiencing an acute aHUS relapse immediately after transplant
  19. Patients receiving Erythrocyte Stimulating Agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period or a of at least 2 weeks from the last dose of ESA therapy.
  20. Participation in any other drug trial or exposure to other investigational agent, device, or procedures beginning 4 weeks prior to screening and throughout the entire trial.
  21. to eculizumab, to murine proteins or to one of the
  22. Patients between ages from 12 and up to 18 years weighing \< 40 kg
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Eculizumab

    Drug: Eculizumab

Interventions

  • All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

06

What researchers measure

Primary outcomes

  1. Platelet Count Change From Baseline to 26 Weeks

    Time frame: From Baseline to 26 weeks

  2. Percentage of Patients With Platelet Count Normalization

    The primary objective of the study (per protocol) was to assess the effect of eculizumab to reduce TMA as measured by platelet count change from baseline (BL) during the Treatment Period (26 weeks) in patients with plasma therapy (PT)-resistant aHUS (protocol defined), including assessment of the proportion of patients who achieved Platelet Count Normalization from baseline through 26 weeks. Platelet Count Normalization was defined as the platelet count observed to be ≥150 x 10\^9/L on at least two consecutive measurements which span a period of at least four weeks.

    Time frame: Through 26 weeks

  3. Percentage of Patients With Hematologic Normalization

    Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.

    Time frame: Through 26 weeks

Secondary outcomes

  1. Percentage of Patients With Complete TMA Response

    The proportion of patients who achieved a Complete TMA Response from baseline through 26 weeks of treatment with eculizumab was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as ≥ 25% reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.

    Time frame: Through 26 weeks

  2. TMA Intervention Rate

    TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through 26 weeks) for PE/PI and (from the fifteenth day following the first eculizumab dose through 26 weeks) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.

    Time frame: Through 26 weeks

  3. Platelet Count Change From Baseline to 156 Weeks

    Time frame: From Baseline to 156 Weeks

  4. Percentage of Patients With Platelet Count Normalization

    Platelet Count Normalization was defined as the platelet count observed to be ≥150 x 10\^9/L on at least two consecutive measurements which span a period of at least four weeks.

    Time frame: Through End of Study, Median Exposure 100.29 Weeks

  5. Percentage of Patients With Hematologic Normalization

    Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.

    Time frame: Through End of Study, Median Exposure 100.29 Weeks

  6. Percentage of Patients With Complete TMA Response

    The proportion of patients who achieved a Complete TMA Response from baseline through end of the study was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as ≥25% reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.

    Time frame: Through End of Study, Median Exposure 100.29 Weeks

  7. TMA Intervention Rate

    TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through end of the study) for PE/PI and (from the fifteenth day following the first eculizumab dose through end of the study) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.

    Time frame: Through End of Study, Median Exposure 100.29 Weeks

  8. Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration

    Time frame: Induction Phase for 4 weeks followed by Maintenance Phase starting on Week 5 through 26 weeks or longer

07

Results

Posted Dec 3, 2014

Participant flow

C08-002A/B combined 2 studies: one for adults (C08-002A, N=16) and one for adolescents (C08-002B, N=1) Please refer to NCT00844545 for combined studies with enrollment number corresponding to each individual study

Screening Period
Participant flow — Screening Period
MilestoneEculizumab
Started17
Completed17
Not completed0
Treatment Period (26 Weeks)
Participant flow — Treatment Period (26 Weeks)
MilestoneEculizumab
Started17
Completed15
Not completed2
Withdrew: Adverse event1
Withdrew: Protocol violation1
Extension Treatment Period
Participant flow — Extension Treatment Period
MilestoneEculizumab
Started13
Completed11
Not completed2
Withdrew: Adverse event2
Post Treatment Period
Participant flow — Post Treatment Period
MilestoneEculizumab
Started6
Completed5
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPlatelet Count Change From Baseline to 26 Weeks
Time frame:
From Baseline to 26 weeks
Reported as:
Least squares mean · 10^9 cells/L
Platelet Count Change From Baseline to 26 Weeks
10^9 cells/LEculizumab
Platelet Count Change From Baseline to 26 Weeks65.18 (37.01 to 93.36)
Statistical analysis
  • Eculizumab · ANOVA · p = <0.0001 · Ls mean change from baseline: 65.18 · 95% CI 37.01 to 93.36Change from baseline were analyzed using a repeated measurement ANOVA model with time and baseline as fixed effects and subject as a random effect.
PrimaryPercentage of Patients With Platelet Count Normalization

The primary objective of the study (per protocol) was to assess the effect of eculizumab to reduce TMA as measured by platelet count change from baseline (BL) during the Treatment Period (26 weeks) in patients with plasma therapy (PT)-resistant aHUS (protocol defined), including assessment of the proportion of patients who achieved Platelet Count Normalization from baseline through 26 weeks. Platelet Count Normalization was defined as the platelet count observed to be ≥150 x 10\^9/L on at least two consecutive measurements which span a period of at least four weeks.

Time frame:
Through 26 weeks
Reported as:
Number · Percentage of Participants
Percentage of Patients With Platelet Count Normalization
Percentage of ParticipantsEculizumab
Percentage of Patients With Platelet Count Normalization82 (57 to 96)
Statistical analysis
  • Eculizumab · Percent of platelet count normalization: 82 · 95% CI 57 to 96
PrimaryPercentage of Patients With Hematologic Normalization

Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.

Time frame:
Through 26 weeks
Reported as:
Number · Percentage of Participants
Percentage of Patients With Hematologic Normalization
Percentage of ParticipantsEculizumab
Percentage of Patients With Hematologic Normalization76 (50 to 93)
Statistical analysis
  • Eculizumab · Percent of hematologic normalization: 76 · 95% CI 50 to 93
SecondaryPercentage of Patients With Complete TMA Response

The proportion of patients who achieved a Complete TMA Response from baseline through 26 weeks of treatment with eculizumab was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as ≥ 25% reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.

Time frame:
Through 26 weeks
Reported as:
Number · Percentage of Participants
Percentage of Patients With Complete TMA Response
Percentage of ParticipantsEculizumab
Percentage of Patients With Complete TMA Response65 (38 to 86)
Statistical analysis
  • Eculizumab · Percent of complete tma response: 65 · 95% CI 38 to 86
SecondaryTMA Intervention Rate

TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through 26 weeks) for PE/PI and (from the fifteenth day following the first eculizumab dose through 26 weeks) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.

Time frame:
Through 26 weeks
Reported as:
Mean · # events/patient/day
TMA Intervention Rate
# events/patient/dayEculizumab
TMA Intervention Rate0.04 ± 0.10
Statistical analysis
  • Eculizumab · Wilcoxon (Mann-Whitney) · p = <0.0001 · Mean difference (final values): -0.78
SecondaryPlatelet Count Change From Baseline to 156 Weeks
Time frame:
From Baseline to 156 Weeks
Reported as:
Least squares mean · 10^9 cells/L
Platelet Count Change From Baseline to 156 Weeks
10^9 cells/LEculizumab
Platelet Count Change From Baseline to 156 Weeks111.62 (98.12 to 125.13)
Statistical analysis
  • Eculizumab · ANOVA · p = <0.0001 · Ls mean change from baseline: 111.62 · 95% CI 98.12 to 125.13Change from baseline was analyzed using a repeated measurement ANOVA model with time and baseline as fixed effects and subject as a random effect.
SecondaryPercentage of Patients With Platelet Count Normalization

Platelet Count Normalization was defined as the platelet count observed to be ≥150 x 10\^9/L on at least two consecutive measurements which span a period of at least four weeks.

Time frame:
Through End of Study, Median Exposure 100.29 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Patients With Platelet Count Normalization
Percentage of ParticipantsEculizumab
Percentage of Patients With Platelet Count Normalization88 (64 to 99)
Statistical analysis
  • Eculizumab · Percent of platelet count normalization: 88 · 95% CI 64 to 99
SecondaryPercentage of Patients With Hematologic Normalization

Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.

Time frame:
Through End of Study, Median Exposure 100.29 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Patients With Hematologic Normalization
Percentage of ParticipantsEculizumab
Percentage of Patients With Hematologic Normalization88 (64 to 99)
Statistical analysis
  • Eculizumab · Percent of hematologic normalization: 88 · 95% CI 64 to 99
SecondaryPercentage of Patients With Complete TMA Response

The proportion of patients who achieved a Complete TMA Response from baseline through end of the study was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as ≥25% reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.

Time frame:
Through End of Study, Median Exposure 100.29 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Patients With Complete TMA Response
Percentage of ParticipantsEculizumab
Percentage of Patients With Complete TMA Response76 (50 to 93)
Statistical analysis
  • Eculizumab · Percent of complete tma response: 76 · 95% CI 50 to 93
SecondaryTMA Intervention Rate

TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through end of the study) for PE/PI and (from the fifteenth day following the first eculizumab dose through end of the study) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.

Time frame:
Through End of Study, Median Exposure 100.29 Weeks
Reported as:
Mean · # events/patient/day
TMA Intervention Rate
# events/patient/dayEculizumab
TMA Intervention Rate0.04 ± 0.11
Statistical analysis
  • Eculizumab · Wilcoxon (Mann-Whitney) · p = <0.0001 · Mean difference (final values): -0.78
SecondaryPharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration
Time frame:
Induction Phase for 4 weeks followed by Maintenance Phase starting on Week 5 through 26 weeks or longer
Reported as:
Mean · micrograms/mil
Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration
micrograms/milEculizumab
max concentration during induction period145.16 ± 26.56
min concentration during induction period93.66 ± 22.10
max concentration during maintenace345.14 ± 89.74
Min concentration during maintenance151.80 ± 68.16

Adverse events

Collected over Through end of study; Exposure to eculizumab in this study extended for a median of 100 weeks and ranged from two weeks to 186 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab—17/17 (100%)17/17 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventEculizumab
Renal impairmentRenal and urinary disorders3/17
HypertensionVascular disorders3/17
Upper respiratory tract infectionInfections and infestations2/17
Accelerated hypertensionVascular disorders2/17
Malignant hypertensionVascular disorders2/17
AnaemiaBlood and lymphatic system disorders1/17
Haemolytic anaemiaBlood and lymphatic system disorders1/17
Haemolytic uraemic syndromeBlood and lymphatic system disorders1/17
LeukopeniaBlood and lymphatic system disorders1/17
PancytopeniaBlood and lymphatic system disorders1/17
Most frequent other events
Showing 10 of 193
Most frequent other events
EventEculizumab
DiarrhoeaGastrointestinal disorders8/17
VomitingGastrointestinal disorders8/17
HeadacheNervous system disorders7/17
HypertensionVascular disorders7/17
AnaemiaBlood and lymphatic system disorders6/17
Urinary tract infectionInfections and infestations6/17
NauseaGastrointestinal disorders5/17
Oedema peripheralGeneral disorders5/17
BronchitisInfections and infestations4/17
Upper respiratory tract infectionInfections and infestations4/17

Baseline characteristics

The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 17 patients who were treated with study drug were included in the ITT population.

Age, Continuous
Age, Continuous(Years)Eculizumab
Mean31.8 ± 13.32
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab
Female12
Male5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eculizumab
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White15
More than one race0
Unknown or Not Reported0
08

Study locations

17 sites
  • Atlanta, Georgia 30322, United States
  • Fort Wayne, Indiana 46804, United States
  • New York, New York 10032, United States
  • New York, New York 10065, United States
  • Grapevine, Texas 76051, United States
  • Houston, Texas 77030, United States
  • Innsbruck, 6020, Austria
  • Bordeaux, 33076, France
  • Lyon, 69437, France
  • Nantes, 44093, France
  • Paris, 75743, France
  • Quimper, 29107, France
  • Saint Priest en Jarez, 42270, France
  • Tours, 37044, France
  • Aachen, 52074, Germany
  • Essen, 45147, Germany
  • Newcastle, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021 Mar 23;3(3):CD012862. doi: 10.1002/14651858.CD012862.pub2. PubMed 33783815 ↗
  • Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981. PubMed 23738544 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Sep 2010 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2009
First posted
Feb 16, 2009
Start
May 2009
Primary completionActual
Sep 2010
CompletionActual
Jul 2013
Results first posted
Dec 3, 2014
Last update
Jul 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00844844
Responsible party
Sponsor
First posted
Feb 16, 2009
Start date
May 2009
Primary completion
Sep 2010
Completion
Jul 2013
Results posted
Dec 3, 2014
Last update
Jul 23, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion